Stroke Prevention with Hydroxyurea Enabled through Research and Education (SPHERE): a Phase 2 primary stroke prevention trial in sub-Saharan Africa.
Smart, LR; Ambrose, EE; Balyorugulu, G; Songoro, P; Shabani, I; Komba, P; Charles, M; Howard, TA; McElhinney, KE; O'Hara, SM; et al.
Acta Haematologica.
2022.
Health Related Quality of Life among Children with Sickle Cell Anaemia in Northwestern Tanzania.
Mwazyunga, Z; Ambrose, EE; Kayange, N; Bakalemwa, R; Kidenya, B; Smart, LR; Hokororo, A.
2022;
12:11-28.
Pediatric Hydrocephalus in Northwest Tanzania: A Descriptive Cross-Sectional Study of Clinical Characteristics and Early Surgical Outcomes from the Bugando Medical Centre.
Aukrust, CG; Parikh, K; Smart, LR; Mdala, I; Fjeld, HE; Lubuulwa, J; Makene, AM; Härtl, R; Winkler, AS.
World Neurosurgery.
2022;
161:e339-e346.
Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.
Quinn, CT; Niss, O; Dong, M; Pfeiffer, A; Korpik, J; Reynaud, M; Bonar, H; Kalfa, TA; Smart, LR; Malik, P; et al.
British Journal of Haematology.
2021;
194:617-625.
Newborn screening for sickle cell disease in sub-Saharan Africa: Is the glass half-full yet?.
Smart, LR; Ware, RE.
Pediatric Blood and Cancer.
2021;
68.
Linkage to Care Intervention to Improve Post-Hospital Outcomes Among Children with Sickle Cell Disease in Tanzania: A Pilot Study.
Hau, DK; Ambrose, EE; Smart, LR; Kayange, NM; Peck, RN.
Journal of Pediatrics.
2021;
232:290-293.e1.
AnemoCheck-LRS: an optimized, color-based point-of-care test to identify severe anemia in limited-resource settings.
Perez-Plazola, MS; Tyburski, EA; Smart, LR; Howard, TA; Pfeiffer, A; Ware, RE; Lam, WA; McGann, PT.
BMC Medicine.
2020;
18.
Surveillance for sickle cell disease, United Republic of Tanzania.
Ambrose, EE; Smart, LR; Charles, M; Hernandez, AG; Latham, T; Hokororo, A; Beyanga, M; Howard, TA; Kamugisha, E; McElhinney, KE; et al.
Bulletin of the World Health Organization.
2020;
98:859-868.
FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease.
Brown, RC; Cruz, K; Kalfa, TA; Kuypers, FA; Saraf, SL; Estepp, JH; Smart, LR; Malik, P; Lerman, M; Mayer, R; et al.
Blood.
2020;
136:19-20.
Extremely high birth prevalence of sickle cell disease in rural Tanzania.
Eastburg, L; Peckham, A; Kawira, E; Chirangi, B; Adler, D; Akungo, BD; Smart, LR; Ambrose, EE.
Pediatric Blood and Cancer.
2020;
67.